Transmitting information to us by e-mail unilaterally does not establish an attorney-client relationship or impose an obligation on either the law firm or even the receiving lawyer to keep the transmitted information confidential. By clicking "OK", you acknowledge that we have no obligation to maintain the confidentiality of any information you submit to us unless we already represent you or unless we have agreed to receive limited confidential material/information from you as a prospective client. Thus, if you are not a client or someone we have agreed to consider as a prospective client, information you submit to us by e-mail may be disclosed to others or used against you. If you would like to discuss becoming a client, please contact one of our attorneys to arrange for a meeting or telephone conference. If you wish to disclose confidential information to a lawyer in the firm before an attorney-client relationship is established, the protections that the law firm will provide to such information from a prospective client should be discussed before such information is submitted. Thank you for your interest in Goodwin Procter.

Goodwin Represents Blackstone Life Sciences in $1.5 Billion Strategic Co-Funding Agreement with Pfizer

main

announcements-lifesciences-goodwin-represents-blackstone-in-pfizer-co-funding-agreement

Goodwin represented Blackstone Life Sciences in a $1.5 billion co-funding agreement with Pfizer to support development of berobenatide for chronic weight management.

Goodwin Represents Blackstone Life Sciences in $1.5 Billion Strategic Co-Funding Agreement with Pfizer

Related Content

Goodwin Advises Zealand Pharma on Entering Into a $100 Million Royalty Purchase and Sale Agreement With Royalty Pharma for the Economics Related to rusfertide

Goodwin Advises Royalty Pharma on Acquiring Royalty Interest in AstraZeneca’s cliramitug for Up To $425 Million From Neurimmune

Goodwin Guides Royalty Pharma on $500 Million R&D Funding Collaboration for Chronic Immune-Mediated Diseases

Goodwin Represents Teva on $400 Million Strategic Growth Capital Agreement With Blackstone Life Sciences to Advance duvakitug

Goodwin Guides Candel Therapeutics on $100 Million Public Offering and $100 Millon Royalty Funding Agreement With RTW

Goodwin Guides Royalty Pharma on Acquisition of Remaining Royalty Interest in Roche’s Evrysdi for $240 Million and Potential Milestones

Goodwin Advised Royalty Pharma in $275 Million Royalty Funding Agreement with Denali Therapeutics

Nanobiotix Seals a Non-dilutive Royalty Financing Agreement for Up to $71 Million

Royalty Monetization in an Era of Drug Pricing Pressure: How the IRA is Affecting Royalty Monetizations

To Monetize or Not to Monetize? The Question Late-Stage Life Sciences Companies Should Be Asking

The Continued Rise of Royalty Deals in Life Sciences

Life Sciences

Life Sciences Royalty Financing